Free Trial Information
BioCentury | Feb 15, 2014
Financial News

Aurinia raises US$52 million in private placement

...RA Capital Management; Great Point Partners; and Apple Tree Partners. Existing investors Lumira Capital; the ILJIN Life Science Co. Ltd....
Read More
BioCentury | Feb 11, 2013
Company News

Aurinia Pharmaceuticals, ILJIN, Isotechnika deal

Isotechnika and Aurinia announced plans to merge in a 60/40 stock deal that will consolidate rights for voclosporin, a cyclosporine analog that inhibits calcineurin . Aurinia was spun out of Vifor Pharma Ltd. last year to...
Read More
BioCentury | Jan 21, 2013
Company News

Isotechnika, ILJIN autoimmune, transplant news

Isotechnika said that ILJIN's ILJIN Life Sciences Co. Ltd. subsidiary has formally withdrawn all claims for damages in the parties' pending arbitration related to the biotech's January 2011 termination of a 2010 deal related to...
Read More
BioCentury | Apr 2, 2012
Company News

Isotechnika, ILJIN autoimmune, transplant news

...Isotechnika said ILJIN's ILJIN Life Science Co. Ltd. subsidiary submitted a request for arbitration related to the biotech's January termination...
Read More
BioCentury | Feb 6, 2012
Company News

Isotechnika, ILJIN deal

...Isotechnika terminated a 2010 deal with ILJIN that granted the pharma's ILJIN Life Science Co. Ltd. subsidiary rights to voclosporin...
Read More
BioCentury | Jan 9, 2012
Company News

Isotechnika, Galenica, ILJIN sales and marketing update

...upfront payment and is eligible to receive milestones and royalties. Details were not disclosed. ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Feb 7, 2011
Company News

Isotechnika, Paladin, ILJIN deal

...is eligible for royalties. Paladin said Isotechnika would sublicense rights in the territories to ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Jan 10, 2011
Clinical News

Voclera voclosporin regulatory update

...transisomer of a cyclosporine analog that inhibits calcineurin in Canada, Israel and South Africa. ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Nov 22, 2010
Company News

Isotechnika, Paladin, ILJIN deal

...Isotechnika granted ILJIN's ILJIN Life Science Co. Ltd. subsidiary exclusive rights to develop and commercialize voclosporin for transplant and autoimmune...
Read More
Items per page:
1 - 9 of 9
BioCentury | Feb 15, 2014
Financial News

Aurinia raises US$52 million in private placement

...RA Capital Management; Great Point Partners; and Apple Tree Partners. Existing investors Lumira Capital; the ILJIN Life Science Co. Ltd....
Read More
BioCentury | Feb 11, 2013
Company News

Aurinia Pharmaceuticals, ILJIN, Isotechnika deal

Isotechnika and Aurinia announced plans to merge in a 60/40 stock deal that will consolidate rights for voclosporin, a cyclosporine analog that inhibits calcineurin . Aurinia was spun out of Vifor Pharma Ltd. last year to...
Read More
BioCentury | Jan 21, 2013
Company News

Isotechnika, ILJIN autoimmune, transplant news

Isotechnika said that ILJIN's ILJIN Life Sciences Co. Ltd. subsidiary has formally withdrawn all claims for damages in the parties' pending arbitration related to the biotech's January 2011 termination of a 2010 deal related to...
Read More
BioCentury | Apr 2, 2012
Company News

Isotechnika, ILJIN autoimmune, transplant news

...Isotechnika said ILJIN's ILJIN Life Science Co. Ltd. subsidiary submitted a request for arbitration related to the biotech's January termination...
Read More
BioCentury | Feb 6, 2012
Company News

Isotechnika, ILJIN deal

...Isotechnika terminated a 2010 deal with ILJIN that granted the pharma's ILJIN Life Science Co. Ltd. subsidiary rights to voclosporin...
Read More
BioCentury | Jan 9, 2012
Company News

Isotechnika, Galenica, ILJIN sales and marketing update

...upfront payment and is eligible to receive milestones and royalties. Details were not disclosed. ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Feb 7, 2011
Company News

Isotechnika, Paladin, ILJIN deal

...is eligible for royalties. Paladin said Isotechnika would sublicense rights in the territories to ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Jan 10, 2011
Clinical News

Voclera voclosporin regulatory update

...transisomer of a cyclosporine analog that inhibits calcineurin in Canada, Israel and South Africa. ILJIN's ILJIN Life Science Co. Ltd....
Read More
BioCentury | Nov 22, 2010
Company News

Isotechnika, Paladin, ILJIN deal

...Isotechnika granted ILJIN's ILJIN Life Science Co. Ltd. subsidiary exclusive rights to develop and commercialize voclosporin for transplant and autoimmune...
Read More
Items per page:
1 - 9 of 9